What is the official website of Novartis Finland ?

The official website of Novartis Finland is https://www.novartis.fi/.

What is Novartis Finland's cybersecurity risk score?

Novartis Finland has an AI-generated cybersecurity risk score of 751 out of 1000, indicating a Fair security posture according to Rankiteo's assessment.

How many security incidents has Novartis Finland experienced?

According to Rankiteo, Novartis Finland currently holds 0 security badges, indicating that no recognized compliance certifications are currently verified for the organization.

Has Novartis Finland been affected by any supply chain cyber incidents ?

According to Rankiteo, Novartis Finland has not been affected by any supply chain cyber incidents, and no incident IDs are currently listed for the organization.

Does Novartis Finland have SOC 2 Type 1 certification ?

According to Rankiteo, Novartis Finland is not certified under SOC 2 Type 1.

Does Novartis Finland have SOC 2 Type 2 certification ?

According to Rankiteo, Novartis Finland does not hold a SOC 2 Type 2 certification.

Does Novartis Finland comply with GDPR ?

According to Rankiteo, Novartis Finland is not listed as GDPR compliant.

Does Novartis Finland have PCI DSS certification ?

According to Rankiteo, Novartis Finland does not currently maintain PCI DSS compliance.

Does Novartis Finland comply with HIPAA ?

According to Rankiteo, Novartis Finland is not compliant with HIPAA regulations.

Does Novartis Finland have ISO 27001 certification ?

According to Rankiteo,Novartis Finland is not certified under ISO 27001, indicating the absence of a formally recognized information security management framework.

Which industry does Novartis Finland operate in ?

Novartis Finland operates primarily in the Pharmaceutical Manufacturing industry.

How many employees does Novartis Finland have ?

Novartis Finland employs approximately 46 people worldwide.

Does Novartis Finland own any subsidiaries ?

Novartis Finland presently has no subsidiaries across any sectors.

How many LinkedIn followers does Novartis Finland have ?

Novartis Finland's official LinkedIn profile has approximately 3,076 followers.

What is the NAICS classification code for Novartis Finland ?

Novartis Finland is classified under the NAICS code 3254, which corresponds to Pharmaceutical and Medicine Manufacturing.

Does Novartis Finland have a Crunchbase profile ?

No, Novartis Finland does not have a profile on Crunchbase.

Does Novartis Finland have a LinkedIn profile ?

Yes, Novartis Finland maintains an official LinkedIn profile, which is actively utilized for branding and talent engagement, which can be accessed here: https://www.linkedin.com/company/novartis-finland.

How many cybersecurity incidents has Novartis Finland experienced ?

As of October 10, 2026, Rankiteo reports that Novartis Finland has experienced 2 cybersecurity incidents.

How many peer or competitor companies does Novartis Finland have ?

Novartis Finland has an estimated 5,774 peer or competitor companies worldwide.

What types of cybersecurity incidents has Novartis Finland faced ?

Incident Types: The types of cybersecurity incidents that have occurred include Breach and Cyber Attack.

Badge your company to reduce your risk score and your cyber insurance costs!

Link verified badges to your company page to build trust with insurers and customers.

Apply now and get your badge!

Internal validation & live display

Insurers and partners see a safer profile

Faster underwriting decisions

Trusted by insurers. Chosen by leaders.

Proud contributor to the Society of Actuaries.

Novartis Finland

Boost Score +25 with badge (5 left)

751

/1000

Fair

776

/1000

Fair

Novartis Finland Vendor Cyber Rating & Cyber Score

novartis.fi

Add Your Compliance Badge

Tehtävämme on pidentää ja parantaa ihmisten elämää. Luomme innovatiivisen tutkimuksen ja digitaalisten teknologioiden avulla uudenlaisia hoitoja vastaamaan merkittäviin lääketieteellisiin tarpeisiin. Toimimme osana terveysalan ekosysteemiä ja olemme avoimia yhteistyölle. Pyrimme kaikessa toiminnassamme korkeaan eettiseen tasoon. LinkedInissa kerromme siitä, mitä teemme ja millaista on työskennellä Novartiksella. Tämän LinkedIn-sivun yhteisösäännöt ja tietosuojailmoitus: www.novartis.fi/linkedin #reimaginingmedicine #novartislife

Novartis Finland

Novartis Finland CyberSecurity News & History

Past Incidents

Attack Types

Entity

Type

Severity

Impact

Seen

Blog Details

Supply Chain Source

Incident Details

View

Novartis

Breach

2/2026

NOV1774449180

Novartis Finland

Cyber Attack

100

06/2022

NOV21267722

Loading…

A.I.

Novartis Finland Company Scoring based on AI Models

Cyber Incidents Likelihood 3 - 6 - 9 months

Actual

Prediction

Incident Predictions locked

Access Monitoring Plan

A.I Risk Score Likelihood 3 - 6 - 9 months

Actual

Prediction A

Prediction B

Prediction C

Prediction D

A.I. Risk Score Predictions locked

Access Monitoring Plan

Loading…

Underwriter Stats for Novartis Finland

Incidents vs Pharmaceutical Manufacturing Industry Avg (This Year)

No incidents recorded for Novartis Finland in 2026.

Incidents vs All-Companies Average (This Year)

No incidents recorded for Novartis Finland in 2026.

Incident Types Novartis Finland vs Pharmaceutical Manufacturing Industry Avg (This Year)

No incidents recorded for Novartis Finland in 2026.

Incident History - Novartis Finland (X = Date, Y = Severity)

Loading…

SUBSIDIARY

Novartis Finland Subsidiaries

Novartis Finland

Pharmaceutical Manufacturing

Website: https://www.novartis.fi/

Company Size: 46

NovartisPharmaceutical Manufacturing

Novartis ItaliaPharmaceutical Manufacturing

Novartis SciencePharmaceutical Manufacturing

Novartis Gene TherapiesBiotechnology Research

Novartis SlovakiaPharmaceutical Manufacturing

Novartis USPharmaceutical Manufacturing

Novartis SlovakiaPharmaceutical Manufacturing

Novartis IndiaPharmaceutical Manufacturing

Novartis MéxicoPharmaceutical Manufacturing

Novartis Gulf | نوفارتس الخليجPharmaceutical Manufacturing

Novartis PortugalPharmaceutical Manufacturing

Novartis, Australia & New ZealandPharmaceutical Manufacturing

Novartis EspañaPharmaceutical Manufacturing

Novartis DeutschlandPharmaceutical Manufacturing

Novartis DanmarkPharmaceutical Manufacturing

Novartis US MedicalPharmaceutical Manufacturing

Novartis SlovakiaPharmaceutical Manufacturing

Novartis ArgentinaPharmaceutical Manufacturing

Novartis SlovakiaPharmaceutical Manufacturing

Novartis SerbiaPharmaceutical Manufacturing

Novartis SverigePharmaceutical Manufacturing

Novartis SingaporePharmaceutical Manufacturing

Novartis Ireland Pharmaceutical Manufacturing

Novartis MagyarországPharmaceutical Manufacturing

Novartis Hong KongPharmaceutical Manufacturing

Novartis MedicalPharmaceutical Manufacturing

Novartis SlovakiaPharmaceutical Manufacturing

Novartis IsraelPharmaceutical Manufacturing

Novartis in SloveniaPharmaceutical Manufacturing

Novartis NorgePharmaceutical Manufacturing

Novartis BrasilPharmaceutical Manufacturing

Novartis RomâniaPharmaceutical Manufacturing

Novartis NederlandPharmaceutical Manufacturing

Novartis Nederland - NeurologieGeneesmiddelenproductie

Novartis Nederland - OncologieGeneesmiddelenproductie

Novartis Nederland - ReumatologieGeneesmiddelenproductie

Novartis Nederland - HematologieGeneesmiddelenproductie

Novartis Nederland - DermatologieGeneesmiddelenproductie

Novartis Nederland - Cardiovascular, Renal & Metabolism Geneesmiddelenproductie

Novartis ColombiaPharmaceutical Manufacturing

Novartis BeluxPharmaceutical Manufacturing

Novartis CanadaPharmaceutical Manufacturing

Novartis SlovakiaPharmaceutical Manufacturing

Loading…

Novartis Finland Similar Companies

Hikma Pharmaceuticals

cb hikma.com

For almost 50 years, we’ve been creating high-quality medicines and making them accessible to the people who need them. We are a trusted, reliable partner and dependable source of over 800* high-quality generic, specialty and branded pharmaceutical products that hospitals, physicians and pharmacists need to treat their patients across North America, MENA and Europe. We have 29 manufacturing plants, 3 R&D hubs and c9,500 employees worldwide. *As of December 2025 Subscribe to our channel on YouTube https://youtube.com/@hikmapharmaceuticals5668 For all product information and enquiries, please contact us at [email protected]

Viatris

viatris.com

Viatris Inc. (NASDAQ: VTRS) is a global healthcare company uniquely positioned to bridge the traditional divide between generics and brands, combining the best of both to more holistically address healthcare needs globally. With a mission to empower people worldwide to live healthier at every stage of life, we provide access at scale. In 2022 alone, we supplied high-quality medicines to approximately 1 billion patients around the world. With our exceptionally extensive and diverse portfolio of medicines, a one-of-a-kind global supply chain designed to reach more people when and where they need them, and the scientific expertise to address some of the world’s most enduring health challenges, access takes on deep meaning at Viatris. We have the ability to touch all of life’s moments, from birth to end of life, acute conditions to chronic diseases. We are headquartered in the U.S., with global centers in Pittsburgh, Shanghai and Hyderabad, India Social Media Guidelines: https://newsroom.viatris.com/social-media-community-guidelines Investors: https://investor.viatris.com Corporate Social Responsibility: https://www.viatris.com/sustainability Connect with Viatris Instagram: https://www.instagram.com/viatrisinc X: https://www.x.com/viatrisinc Viatris and our recruiting firms will not ask for sensitive personal information, such as your social security number, date of birth or bank account details via text, email or social media. Additionally, Viatris representatives do not request payment or personal bank information nor send payment to purchase hardware on your own. Viatris.com is the primary source of all company job postings and authorized third-party career websites.

Sandoz

sandoz.com

Sandoz is the global leader in generic and biosimilar medicines. Our Purpose is to pioneer access to medicines for patients globally. We are on a mission to drive innovation in the healthcare industry by freeing up resources sustainably and responsibly while continuing to address global health challenges such as antimicrobial resistance. We are present in more than 100 countries and our medicines serve some 500 million people every year. We have two main global businesses: Generics - divided between standard generics and complex generics - and Biosimilars. Read our community engagement guidelines: http://bit.ly/4ofoggc

MSD

msd.com

At MSD, known as Merck & Co., Inc., Rahway, NJ, USA in the United States and Canada, we are unified around our purpose: We use the power of leading-edge science to save and improve lives around the world. For more than 130 years, we have brought hope to humanity through the development of important medicines and vaccines. We aspire to be the premier research-intensive biopharmaceutical company in the world – and today, we are at the forefront of research to deliver innovative health solutions that advance the prevention and treatment of diseases in people and animals. We foster a diverse and inclusive global workforce and operate responsibly every day to enable a safe, sustainable and healthy future for all people and communities. For more information, visit www.msd.com and connect with us on Facebook, Instagram, Twitter, and YouTube.

Fresenius Kabi

fresenius-kabi.com

As a global healthcare company, Fresenius Kabi is Committed to Life. The company’s products, technologies, and services are used for the therapy and care of critically and chronically ill patients. With over 41,000 employees and present in over 100 countries, Fresenius Kabi’s expansive product portfolio focuses on providing access to high-quality and lifesaving medicines and technologies. In Biopharma, Fresenius Kabi offers cutting-edge biosimilars for autoimmune diseases and oncology. With leading market positions in Medical Nutrition, a broad portfolio of enteral and parenteral products makes a distinct difference in patients’ nutritional status. In MedTech, the company provides vital infusion pumps, cell and gene therapy devices, disposables, and more. Fresenius Kabi is the global leader in supplying blood collection bags and devices, supporting blood banks and healthcare facilities worldwide. The company’s I.V. Generics and Fluids for infusion therapy help save millions of lives every year, in emergency medicine, surgery, oncology, and intensive care. Fresenius Kabi takes a holistic approach to healthcare and uniquely combines experience, expertise, innovation, and dedication – making a difference in the lives of 450 million patients annually. With the #FutureFresenius strategy, the company is developing, producing, and selling new products and technologies and aspires to expand its position as a leading global provider of therapies, improve patient care, generate sustainable value for stakeholders – shaping the future of healthcare. Fresenius Kabi is an operating company of the Fresenius Group, founded in 1912, along with Helios and Quirónsalud. As ONE team, the companies in the Fresenius Group are committed to providing lifesaving and life-changing healthcare solutions on a global scale. User information & community guidelines: https://www.fresenius-kabi.com/social-media-terms-conditions Imprint: www.fresenius-kabi.com/imprint

AbbVie

cb abbvie.com

AbbVie is a global biopharmaceutical company focused on creating medicines and solutions that put impact first — for patients, communities, and our world. We aim to address complex health issues and enhance people's lives through our core therapeutic areas: immunology, oncology, neuroscience, aesthetics and other areas of unmet need. Learn more about us at www.abbvie.com and review our community guidelines at https://www.abbvie.com/social-media-community-guidelines.html.

Bristol Myers Squibb

cb bms.com

At Bristol Myers Squibb, we work every day to transform patients’ lives through science. That work inspires some of the most interesting, meaningful, and life-changing careers you’ll experience. Join us and pursue innovative ideas alongside some of the brightest minds in biopharma, collaborating with a team rich in diversity of experiences, and perspectives. We have built a sustainable pipeline of potential therapies and are leveraging translational medicine and data analytics to understand how we can deliver the right medicine to the right patient, at the right time, to achieve the best outcome. Whether in a scientific, business or supporting function, a career at BMS means you’ll be inspired every day to grow and thrive through opportunities that are uncommon in scale and scope. Here, you’ll be on the cutting edge of powerful innovation in oncology, hematology, immunology, cardiovascular disease, and fibrosis, with colleagues united in the mission to help patients. Through the Bristol Myers Squibb Foundation, we also promote health equity and seek to improve health outcomes of populations disproportionately affected by serious diseases and conditions. Our mission is to give new hope to help patients prevail over serious disease – it drives everything we do. Review our Social Media Community Guidelines at: https://www.bms.com/social-media-community-guidelines.html

Catalent

catalent.com

Championing the missions that matter™. Catalent, Inc. is a leading global contract development and manufacturing organization (CDMO) and trusted partner to pharma, biotech, and consumer health companies worldwide. We put patients first in everything we do, helping people live better and healthier lives through every product we help develop, manufacture and deliver. With over 1,000 active development programs at any given time, we launch over 100 new products and line extensions annually. Catalent has supported half of all FDA approvals over the past decade, and our teams working at over 40 global sites help us produce over 60 billion doses every year. Our strength lies in our people: teams across our more than 40 sites and thousands of passionate scientists and technicians who bring expertise in development sciences, delivery technologies, and multi-modality manufacturing. What unites us is our commitment to championing our partners’ missions as our own, anticipating customer needs, solving complex challenges and ultimately making a difference in the lives of patients across the globe. At Catalent, you will be able to directly have an impact, solving problems and ensuring excellence for our customers. Our focus on delivering meaningful outcomes alongside our customers means your work directly impacts millions of people around the world. Join us in championing the missions that matter. Catalent is headquartered in Tampa, Florida, with over 40 global sites. Visit www.catalent.com to learn more.

Johnson & Johnson Innovative Medicine

jnj.com

At Johnson & Johnson Innovative Medicine, we innovate with purpose, to lead where medicine is going. The experiences of patients around the world inform and inspire our science-based innovations, which continue to change and save lives. Applying rigorous science with compassion, we confidently address the most complex diseases of our time and develop the potential medicines of tomorrow. We are continuously working to develop treatments, aspiring to find cures, pioneering the path from lab to life, and championing patients every step of the way. https://bit.ly/3reuMvK

Loading…

NEWS

Novartis Finland CyberSecurity News

Latest updates, reports, and threat intel affecting the global network.

Loading…

CVE

Latest

Global CVEs (Not Company-Specific)

CVE-2026-22061

SUMMARY

Trident versions v25.02.1 through v26.06.1 are susceptible to a vulnerability that could allow an authenticated attacker with access to debug logs to view LUKS passphrases or SMB Active Directory credentials.

Published

Date2026-10-09

Updated

Date2026-10-09

RISK INFORMATION (Score: )

cvss4

Base Score: 8.2

Complexity: LOW

CVSS:4.0/AV:L/AC:L/AT:N/PR:L/UI:N/VC:H/VI:N/VA:N/SC:H/SI:N/SA:N/E:X/CR:X/IR:X/AR:X/MAV:X/MAC:X/MAT:X/MPR:X/MUI:X/MVC:X/MVI:X/MVA:X/MSC:X/MSI:X/MSA:X/S:X/AU:X/R:X/V:X/RE:X/U:X

Impact Score

Exploitability

REFERENCES

https://security.netapp.com/advisory/NTAP-20261009-0026

CVE-2026-108269

SUMMARY

Remote Attestation TLS Clients provides multi-language utilities for verifying attested TLS connections. Prior to 0.5.0, the Rust and Go RA-TLS challenge verifiers accepted quote ReportData that was bound to the certificate public key and client nonce but not to the active TLS session before permitting application traffic. An attacker who obtained an enclave TLS private key could relay a genuine quote onto another connection, causing the clients to accept an attacker-terminated connection as the attested enclave. This issue is fixed in 0.5.0.

Published

Date2026-10-09

Updated

Date2026-10-09

RISK INFORMATION (Score: )

cvss4

Base Score: 9.1

Complexity: HIGH

CVSS:4.0/AV:N/AC:H/AT:P/PR:N/UI:N/VC:H/VI:H/VA:N/SC:N/SI:N/SA:N/E:X/CR:X/IR:X/AR:X/MAV:X/MAC:X/MAT:X/MPR:X/MUI:X/MVC:X/MVI:X/MVA:X/MSC:X/MSI:X/MSA:X/S:X/AU:X/R:X/V:X/RE:X/U:X

Impact Score

Exploitability

REFERENCES

CVE-2026-108268

SUMMARY

Enclave OS Virtual runs container workloads inside confidential virtual machines with end-to-end attestation. Prior to tdx-v0.2.43 and tdx-gpu-v0.6.27, the TDX/GPU RA-TLS certificate issuer placed the certificate public-key hash and client nonce in quote ReportData but omitted a value bound to the active TLS session. An attacker who obtained an enclave TLS private key could relay a genuine quote onto another connection, causing a relying party to accept an attacker-terminated connection as the attested enclave. This issue is fixed in tdx-v0.2.43 and tdx-gpu-v0.6.27.

Published

Date2026-10-09

Updated

Date2026-10-09

RISK INFORMATION (Score: )

cvss4

Base Score: 9.1

Complexity: HIGH

CVSS:4.0/AV:N/AC:H/AT:P/PR:N/UI:N/VC:H/VI:H/VA:N/SC:N/SI:N/SA:N/E:X/CR:X/IR:X/AR:X/MAV:X/MAC:X/MAT:X/MPR:X/MUI:X/MVC:X/MVI:X/MVA:X/MSC:X/MSI:X/MSA:X/S:X/AU:X/R:X/V:X/RE:X/U:X

Impact Score

Exploitability

REFERENCES

CVE-2026-108267

SUMMARY

Privasys Go is a maintained fork of the Go programming language that adds RA-TLS support to crypto/tls. Prior to privasys-v0.5.1-go1.26.5, challenge-mode RA-TLS certificates bound quote ReportData to the certificate public key and client nonce but not to the active TLS session. An attacker who obtained an enclave TLS private key could relay a genuine quote onto another connection, causing a relying party to accept a handshake terminated by the attacker as an attested enclave connection. This issue is fixed in privasys-v0.5.1-go1.26.5.

Published

Date2026-10-09

Updated

Date2026-10-09

RISK INFORMATION (Score: )

cvss4

Base Score: 9.1

Complexity: HIGH

CVSS:4.0/AV:N/AC:H/AT:P/PR:N/UI:N/VC:H/VI:H/VA:N/SC:N/SI:N/SA:N/E:X/CR:X/IR:X/AR:X/MAV:X/MAC:X/MAT:X/MPR:X/MUI:X/MVC:X/MVI:X/MVA:X/MSC:X/MSI:X/MSA:X/S:X/AU:X/R:X/V:X/RE:X/U:X

Impact Score

Exploitability

REFERENCES

CVE-2026-92705

SUMMARY

Aegisub is a cross-platform advanced subtitle editor. From 3.2.0 to 3.4.2, Aegisub automatically loads Automation scripts referenced by `Automation Scripts` metadata in `ASS` subtitle projects without asking whether the user trusts the scripts or their authors. An attacker can distribute a crafted `ASS` file together with a referenced malicious Automation script, and opening the `AS` file executes arbitrary code with the privileges of the Aegisub process. From 3.4.0 to 3.4.2, inconsistent handling of embedded `NUL` characters between extension validation and filesystem operations additionally allows a crafted `ASS/Lua` polyglot to reference and execute itself as a single-file variant. The vulnerability is fixed in Aegisub 3.5.0.

Published

Date2026-10-09

Updated

Date2026-10-09

RISK INFORMATION (Score: 7.8)

cvss3

Base Score: 7.8

Complexity: LOW

CVSS:3.1/AV:L/AC:L/PR:N/UI:R/S:U/C:H/I:H/A:H

Impact Score

5.9

Exploitability

1.8

REFERENCES

Loading…

API

Access Data Using Our API

Get company history

curl -i -X GET 'https://api.rankiteo.com/underwriter-getcompany-history?
linkedin_id=axa' -H 'apikey: YOUR_API_KEY_HERE'

Try It API Documentation Rapid

MEASURE

What Do We Measure ?

Incident

Finding

Grade

Digital Assets

Every week, Rankiteo analyzes billions of signals to give organizations a sharper, faster view of emerging risks. With deeper, more actionable intelligence at their fingertips, security teams can outpace threat actors, respond instantly to Zero-Day attacks, and dramatically shrink their risk exposure window.

These are some of the factors we use to calculate the overall score:

Network SecurityIdentify exposed access points, detect misconfigured SSL certificates, and uncover vulnerabilities across the network infrastructure.

SBOM (Software Bill of Materials)Gain visibility into the software components used within an organization to detect vulnerabilities, manage risk, and ensure supply chain security.

CMDB (Configuration Management Database)Monitor and manage all IT assets and their configurations to ensure accurate, real-time visibility across the company's technology environment.

Threat IntelligenceLeverage real-time insights on active threats, malware campaigns, and emerging vulnerabilities to proactively defend against evolving cyberattacks.

Rankiteo

By Rankiteo

★ ★ ★ ★ ★

View on G2.com

Rankiteo is a unified scoring and risk platform that analyzes billions of signals weekly to help organizations gain faster, more actionable insights into emerging threats. Empowering teams to outpace adversaries and reduce exposure.

View latest plans →View all security reports →

MILESTONEG

Users
Love Us

Loading…

Badge your company to reduce your risk score and your cyber insurance costs!

Trusted by insurers. Chosen by leaders.

Novartis Finland Vendor Cyber Rating & Cyber Score

Novartis Finland A.I CyberSecurity Scoring

Novartis Finland CyberSecurity News & History

Novartis Finland Company Scoring based on AI Models

Cyber Incidents Likelihood 3 - 6 - 9 months

Incident Predictions locked

A.I Risk Score Likelihood 3 - 6 - 9 months

A.I. Risk Score Predictions locked

Underwriter Stats for Novartis Finland

Incidents vs Pharmaceutical Manufacturing Industry Avg (This Year)

Incidents vs All-Companies Average (This Year)

Incident Types Novartis Finland vs Pharmaceutical Manufacturing Industry Avg (This Year)

Incident History - Novartis Finland (X = Date, Y = Severity)

Novartis Finland Subsidiaries

Novartis Finland

Novartis Finland Similar Companies

Hikma Pharmaceuticals

Viatris

Sandoz

MSD

Fresenius Kabi

AbbVie

Bristol Myers Squibb

Catalent

Johnson & Johnson Innovative Medicine

Novartis Finland CyberSecurity News

Global CVEs (Not Company-Specific)

Access Data Using Our API

What Do We Measure ?

These are some of the factors we use to calculate the overall score:

Rankiteo

Novartis Finland CyberSecurity News & History

Novartis Finland Company Scoring based on AI Models

Cyber Incidents Likelihood 3 - 6 - 9 months

Incident Predictions locked

A.I Risk Score Likelihood 3 - 6 - 9 months

A.I. Risk Score Predictions locked

Underwriter Stats for Novartis Finland

Incidents vs Pharmaceutical Manufacturing Industry Avg (This Year)

Incidents vs All-Companies Average (This Year)

Incident Types Novartis Finland vs Pharmaceutical Manufacturing Industry Avg (This Year)

Incident History - Novartis Finland (X = Date, Y = Severity)

Novartis Finland Subsidiaries

Novartis Finland

Novartis Finland Similar Companies

Hikma Pharmaceuticals

Viatris

Sandoz

MSD

Fresenius Kabi

AbbVie

Bristol Myers Squibb

Catalent

Johnson & Johnson Innovative Medicine

Novartis Finland CyberSecurity News

Global CVEs (Not Company-Specific)

Access Data Using Our API

What Do We Measure ?

These are some of the factors we use to calculate the overall score:

Rankiteo